Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Ericsson's Nomination Committee appointed

Ericsson’s (NASDAQ:ERIC) Nomination Committee for the Annual General Meeting 2019 has been appointed in accordance with the Instruction for the Nomination Committee resolved by the Annual General Meeting 2012. The Nomination Committee consists of: · Johan Forssell, Investor AB; · Bengt Kjell, AB Industrivärden and Svenska Handelsbankens Pensionsstiftelse; · Christer Gardell, Cevian Capital Partners Limited; · Anders Oscarsson, AMF – Försäkring och Fonder; and · Ronnie Leten, the Chairman of the Board of Directors. Johan Forssell is the Chairman of the Nomination

Notice to attend the Annual General Meeting of Shareholders of DDM Holding AG

The shareholders of DDM Holding AG (First North: DDM), (the “Company”), are hereby convened to the 2018 Annual General Meeting (the “AGM”) to be held on Wednesday, 23 May 2018 at 9:00 a.m. CET, at the premises of Parkhotel Zug, Industriestrasse 14, 6300 Zug, Switzerland. The doors will open at 8:30 a.m. CET.The shareholders are cordially invited to review the various ways to participate at the AGM and cast their vote. Detailed information on this and the agenda items can be found in the attached invitation to the AGM, also available on the Company’s website, http://ddm-group.ch/investors.

Asarina Pharma: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD

Stockholm – April 24, 2018. The first patients arrived in clinics in Krakow, Poland and Berlin, Germany to take part in Phase IIB trials of the world’s first treatment for PMDD. CEO Peter Nordkild: “This is a milestone moment. Already having patients in the clinic, only ten days after the study opened, underlines the powerful need for a treatment that will alleviate the misery of the severest form of PMS.”The phase IIB study is recruiting 225-250 patients from Sweden, UK, Germany and Poland, to trial Sepranolone in PMDD. It’s an endogenous compound, naturally occurring in the brain, which

Duni and Mitt Liv: a partnership that contributes to positive change in society

Duni and Mitt Liv (My Life) have created a partnership that aims to enhance Duni’s work on diversity. Mitt Liv is a social enterprise that strives to achieve an inclusive society and a labor market that values diversity.“We have chosen to collaborate with Mitt Liv, which we believe is an effective organization that is making a difference. We want to make an active contribution towards a positive change in society, and we hope that the partnership with Mitt Liv will enable us to achieve this,” says Sofie Lindström, HR Director at Duni. Sofie confirms that Duni is a global company and the

Annual Report 2017

The Annual Report 2017 is now available.An international conference call for investors and analysts will be held on May 3, 2018 at 3:00 pm CET. The dial-in numbers are US + 1 212 999 6659, UK +44 (0) 20 3003 2666 and Sweden +46 (0) 8 505 204 24 using the meeting code: Corral. For further information, please contact:Amelie Wilson                                                        Investor Relations Manager                                          Tel: + 46 (0)10-450 10 21                                                 Email: amelie.wilson@preem.se

Newsletter  -  Manufacturing of Alpha1H drug product and Placebo has been successfully completed and are ready for clinical use

Hamlet Pharma is happy to announce that the drug product Alpha1H and the corresponding Placebo have been successfully manufactured by the Contract Manufacturing Organization (CMO) Recipharm to be used in the clinical trial. A certificate of analysis has been issued and the manufactured drug product batch is fully active against tumor cells.Hamlet Pharma has selected Recipharm to develop and manufacture the Alpha1H drug product based on their excellent reputation in the Life Science community and their global representation, which may be beneficial for future development and scale up of the

Manufacturing and construction lift indicator in april

After falling for four months, the Economic Tendency Indicator climbed 1.6 points in April to 110.4, reflecting much stronger sentiment than normal among Swedish businesses and consumers.The improvement was due mainly to even stronger signals from the manufacturing industry. The manufacturing indicator jumped 5.1 points in April, driven by an upward revision of production plans for the next three months and firms being less unhappy about stocks of finished goods. The building and civil engineering industry also contributed to the overall improvement, its indicator climbing for a second

Nordnet interim report January-March 2018

Nordnet today publishes its interim report for January-March 2018. The full report is available at nordnetab.com .Highlights during the quarter  · Strong customer growth despite turbulent stock market - 29,200 new customers choose to start saving at Nordnet during the quarter · Highest net savings for one single quarter – 11.5 billion · We welcomed 3,500 visitors to the Nordic region’s largest savings event - Nordnet Live · Nordnet moves headquarters into new premises on Alströmergatan 39, Kungsholmen in Stockholm Financial results in brief,

INVISIO Interim Report January–March 2018: Continued focus on growth and stable underlying business

Stockholm, April 26, 2018 CEO comment”INVISIO is continuing its long-term work of increasing market presence, establishing even stronger relations with customers and cooperating with them to develop innovative product solutions. Our underlying business has been stable during the quarter, both in the form of follow-up orders from existing customers and orders from new customers. Sales are on a level close to the strong comparative quarter of 2017”, says Lars Højgård Hansen, CEO of INVISIO.January–March 2018 · Revenue: SEK 84.2 m (87.9) · Gross profit: SEK 50.1 m (48.2) ·

Cereno Scientific requests first convertible loan from European High Growth Opportunities Securitization Fund

The board of directors of Cereno Scientific AB (publ) (“Cereno”) has requested the issuance of the first tranche of convertible bonds with warrants attached, amounting to SEK 5,000,000, to European High Growth Opportunities Securitization Fund, in accordance with the financing solution announced by Cereno through a press release on 19 March 2018.Convertible Instruments The board has resolved, based on the general meeting’s authorization, to request the issuance of the first tranche of convertible loan amounting to SEK 5 million by issuing convertible instruments. The convertible

Hunter Group ASA – Enters into definitive VLCC contract transfer agreements with Apollo Asset Ltd.

Oslo, 26 April 2018  General Reference is made to previous announcements concerning the non-binding indicative offer from Apollo Asset Ltd. (“Apollo”), upon which Apollo, a company controlled by board member Arne Fredly, indicated its willingness to transfer four (4) VLCC shipbuilding contracts and options for up to three (3) more VLCC shipbuilding contracts to Hunter Group ASA, as first announced on 10 April 2018 at 08:53 (the “OSE Notice”).  The board of directors of the Company has today signed a definitive back-to-back contract transfer agreement (the “Contract Transfer

New date for publication of interim report January-March 2018 and updated financial calendar

The release of Camanio's interim report January-March 2018 will be moved from May 25 to May 15 due to coordination with Camanio's principal owners reporting.Due to this coordination, the company also moves the publication of the Interim Report July-September 2018 from November 23 to November 15, 2018. Financial calendar 2018: May 15, 2018                     Interim report January-March 2018 August 24, 2018                 Interim report April-June 2018 November 15, 2018           Interim report July-September 2018 February 27, 2019              Year-end report 2018 For

Invitation to conference call with web presentation of Cinnober’s interim report Q1 2018

Cinnober will publish the interim report for the period 1 January – 31 March 2018 before the markets open on Thursday 3 May.  At 11:00 (CET) on Thursday 3 May, Veronica Augustsson, CEO, and Peter Lenardos, Senior Financial Advisor, will present and comment on the report by a conference call/audiocast. There will be the possibility to ask questions afterwards and the presentation will be held in English. · Time: Thursday May 3, 2018 at 11.00 CET  · Webcast: https://tv.streamfabriken.com/cinnober-q1-2018  · Teleconference: Dial-in number UK: +442030089809 SE: +46851999031 US:

UPM Interim Report Q1/2018: UPM continues to grow earnings - Strong customer demand in all businesses

UPM-Kymmene Corporation      Interim Report         26 April 2018 at 09:40 EET UPM Interim Report Q1/2018: UPM continues to grow earningsStrong customer demand in all businesses Q1 2018 highlights · Comparable EBIT increased by 17% to EUR 355 million (305 million in Q1 2017). · Sales prices increased in all business areas, outweighing the impact of higher input costs and unfavourable currencies. · Operating cash flow was EUR 208 million (396 million), including an increase in working capital. · Net debt decreased to EUR 41 million (807 million). Key figures

Continued strong demand

I am delighted to begin my first report by announcing that the first quarter of 2018 was the strongest quarter to date in Beijer Alma’s history. The Group’s order bookings, invoicing and earnings all improved. Order bookings increased 20 percent, invoicing 7 percent and earnings 13 percent.Within Lesjöfors’s Industry Springs business area, invoicing rose 9 percent, with Sweden and Germany representing particularly strong markets. Invoicing in the Chassis Springs business area increased 14 percent. Customer demand was strong for both business areas, and we are well positioned to capitalize

Annual General Meeting of BioGaia

The Annual General Meeting of BioGaia AB (publ) on 25 April 2018 voted to approve the following resolutions: · adoption of the annual report · discharge from liability for the Board members and the Managing Director · a dividend of SEK 9.00 per share and a grant of not more than SEK 2.7 million to “The foundation to prevent antibiotic resistance” that was founded 2017. The purpose of the foundation is to reduce antibiotic resistance through support to research, education and information activities that promote of the use of products and methods that prevent infections and reduce

Interim Report 1 January–31 March 2018

GROWTH, HIGHER EARNINGS AND STRONG CASH FLOW IN Q1FIRST QUARTER SUMMARY, JANUARY–MARCH 2018 ·  Net sales increased to SEK 737 m (619), up 19 per cent. ·  EBITA increased to SEK 66 m (52), for an EBITA margin of 9.0 per cent (8.4). ·  Operating profit increased to SEK 44 m (35), or an operat­ing margin of 6.0 per cent (5.7). ·  Profit after tax increased to SEK 29 m (26). ·  Earnings per share after dilution increased to SEK 0.95 (0.85). ·  Cash flow from operating activities increased to SEK 205 m (180). SUMMARY OF SIGNIFICANT EVENTS DURING THE FIRST QUARTER, JANUARY–

Episurf Medical enters into distribution agreement in Hong Kong and establishes subsidiary in the US

Episurf Medical (NASDAQ: EPIS B) today announces that the company has entered into a distribution agreement in Hong Kong with Pacific Medical Systems. This is a first step in the company’s strategy of opening new markets in Asia. Pål Ryfors, CEO Episurf Medical, says that “we have received very encouraging feedback from leading surgeons in Hong Kong, confirming that Episealer® will help them to treat patients in the so-called treatment gap. We are happy to have appointed Pacific Medical Systems as our distributor, and Hong Kong will, as our first market in Asia where our technology is ready

Interim report Pricer AB January-March 2018

Improved net sales, operating margin and cash flowFirst quarter 2018 · Net sales of SEK 180.0 M (174.2), an increase of 3 percent compared to the same period of last year  · Operating profit of SEK 9.0 M (7.2), corresponding to an operating margin of 5.0 percent (4.2)  · Order intake of SEK 189 M (189), in parity to the same period last year  · The order backlog increased to SEK 143 M (103), most of which is expected to be invoiced in the next quarter  · Profit for the period amounted to SEK 5.8 M (4.0)  · Earnings per share amounted to SEK 0.05 (0.04)  · Cash flow

SUMMONS TO THE ANNUAL GENERAL MEETING IN VIKING SUPPLY SHIPS AB

26 April 2018Shareholders of Viking Supply Ships AB (publ) are hereby invited to the Annual General Meeting on Wednesday, May 30, 2018, at 16.00 at Radisson Blu Scandinavia, Södra Hamngatan 59, Gothenburg. The premises will open at 15.30. Notification etc. Shareholders who wish to participate in the Annual General Meeting must be recorded in the share register maintained by Euroclear Sweden AB on Thursday, May 24, 2018, and notify the company of their intention to participate in the Annual General Meeting no later than on Thursday, May 24, 2018 (preferably before 4 p.m.), ·  by

Release of Annual report in Viking Supply Ships AB (publ)

Press release 26 April 2018The group’s net sales decreased year-on-year to MSEK 331 (760), net result after tax was MSEK -332 (-406). QUARTER 1 ·  The bond settlement by way of cash redemption and the set-off equity issue in VSS AB was completed on 12 January 2017. Under the settlement, bondholders of record as of 30 December 2016 (the “Record Date”) received 36,821,058 new class B-shares in VSS AB and NOK 34,419,682.96 in cash as payment of the total outstanding principal amount – NOK 199,341,169, and holders as of the date of the Record Date of the right to receive interest

Interim report January – March 2018

NET ASSET VALUE AND THE LATOUR SHARE ·The net asset value rose to SEK 99 per share, compared with SEK 95 per share at the beginning of the year. This is an increase of 4.1 per cent. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) decreased by 0.5 per cent. The net asset value was SEK 97 per share at 25 April. (1) ·In the period, the total return on the Latour share fell by 6 per cent measured against the SIXRX, which was down by 0.5 per cent. INDUSTRIAL OPERATIONS ·The industrial operations' order intake rose 14 per cent to SEK 2,752 m (2,426

Positive evaluation of first project results in additional sales to existing customer - ChromoGenics receives a repeat order

ChromoGenics AB (publ) has signed a repeat order with Saldeen Real Estate AB of approximately 40 sqm of dynamic glass to another office in Uppsala for delivery during the second quarter of 2018. The evaluation of the project delivered in June 2017 shows increased indoor comfort, which has resulted in a repeat order."The office was built as late as 2016 with 3-glass units including a static solar protection. The tenant experienced the indoor climate too dark during the winter and in a comparative evaluation of the two adjacent properties, better climate and indoor comfort were found in the

Thai entertainment portal Kapook.com signs agreement for Cxense software

Oslo, Norway – 26 April 2018 – Cxense ASA (OSE: CXENSE) today announced that the leading Thai lifestyle, entertainment and news portal Kapook.com signed an agreement with Cxense for the use of its Data Management Platform with Intelligent Personalization software. Kapook operates one of Thailand's most popular sites with about 150 million monthly page views and 30 million unique visitors. Kapook.com will use the Cxense software to develop richer user profiles, increase audience engagement and online revenue generation. About Cxense:Cxense helps publishers and marketers across the

There are no items matching the current filter
There are no more items matching the current filter
Back to top